In October 2000, two hexavalent vaccines (Hexavac, Sanofi Pasteur MSD and Infanrix Hexa, GlaxoSmith Kline) were licensed in the European Union for vaccinating children against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive infections caused by Haemophilus influenzae b. In September 2005, Hexavac was suspended by the European Medicines Agency (EMA) because of concerns o...